Rana Ayad Ghaleb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rana Ayad Ghaleb has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Ali M. Jaafar Abdulsahib
Department of Pharmacology, College of Pharmacy, University of Alameed, Karbala, Iraq
1 shared publication- Ali N. Wannas
Department of Pharmaceutics, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
1 shared publication Nisreen Jalal Mohammed
Department Pharmacology, College of Medicine, University of Babylon, Hillah, Iraq
1 shared publicationSabah H Enayah
Department of Biology, College of Science, University of Thi-Qar, Nasiriyah, Iraq
1 shared publicationSarah K Obayes
Department of Pharmacology and Toxicology, College of Pharmacy, University of Kufa, Kufa, Iraq
1 shared publication- Sarah K. Obayes
Department of pharmacology and toxicology, Faculty of Pharmacy, University of Kufa, Al-Najaf, Iraq
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Wolters Kluwer Health in Medical Journal of Babylon
- Vol. 22 (2) , 322-326
The Combination Effect of Chemotherapy Drug with Febuxostat and Curcumin on Colon Cancer Cell line (LS174T)
Background: Colorectal cancers are the 3rd highest commonly discovered form of cancer worldwide. The outcomes of various studies have revealed that cancer cells growth has been affected in response to treatment. In this study, the in vitro cytotoxic effects of different drug combinations [5-fluorouracil (5-FU), curcumin, and febuxostat] were measured by crystal violet method. The results showed significant anticancer activity on LS174T colorectal cancer cell line at different combinations. Objective: This study aimed to assess the cytotoxic effect of different combinations of 5-FU, curcumin, and febuxostat on colorectal cancer LS174 cell line. Materials and Methods: For 24 h, the human colon cancer cell line LS174T was given a variety of doses of combinations of 5-FU, febuxostat, and curcumin. Crystal violet assay was used to assess the cytotoxicity of the combined agents extract against colon cancer cells. Results: 5-FU, curcumin, and febuxostat when used in different combinations concentrations, showed respectable anticancer effect on colorectal cancer LS174T cell line. Conclusion: The current study indicated that the good anticancer effects of combined agents when used to treat colorectal cancer.
- 1 April 2025
- Published by Wolters Kluwer Health in Medical Journal of Babylon
- Vol. 22 (2) , 322-326
Open AccessThe Combination Effect of Chemotherapy Drug with Febuxostat and Curcumin on Colon Cancer Cell line (LS174T)
Background: Colorectal cancers are the 3rd highest commonly discovered form of cancer worldwide. The outcomes of various studies have revealed that cancer cells growth has been affected in response to treatment. In this study, the in vitro cytotoxic effects of different drug combinations [5-fluorouracil (5-FU), curcumin, and febuxostat] were measured by crystal violet method. The results showed significant anticancer activity on LS174T colorectal cancer cell line at different combinations. Objective: This study aimed to assess the cytotoxic effect of different combinations of 5-FU, curcumin, and febuxostat on colorectal cancer LS174 cell line. Materials and Methods: For 24 h, the human colon cancer cell line LS174T was given a variety of doses of combinations of 5-FU, febuxostat, and curcumin. Crystal violet assay was used to assess the cytotoxicity of the combined agents extract against colon cancer cells. Results: 5-FU, curcumin, and febuxostat when used in different combinations concentrations, showed respectable anticancer effect on colorectal cancer LS174T cell line. Conclusion: The current study indicated that the good anticancer effects of combined agents when used to treat colorectal cancer.
- Open Access
- 1 January 2024
- Published by Medknow in Medical Journal of Babylon
- Vol. 21 (1) , 52-56
Detection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical methods
Background: MicroRNA (miRNA) is a short, single-stranded, non-coding sequence of RNA that does not translate into proteins. Because of their ability to control gene expression, recent studies have shown that these short, non-coding sequences play an important role in cancer. So that, detection the polymorphisms or variants in miRNA genes may help to identify their correlation to cancer susceptibility. Objectives: Study the polymorphisms in miRNA genes or variants miRNA genes and their correlation with myeloma disease. Materials and Methods: Twenty samples were collected from people who visited Marjan Hospital in Province of Babylon, Iraq, from February to July 2022. In addition, 20 samples from healthy people were collected as control. Genotyping of miRNA was accomplished using the polymorphism techniques of polymerase chain reaction and single strand conformation polymorphism (SSCP). DNA sequencing was also applied to categorize all the ranges of SSCP models detected using only gel imaging. Results: The genotypes obtained in this experiment verified that several single nucleotide polymorphisms were obtained between 5-band and 6-band miRNA National center for biotechnology information Primer3 plus reference. Conclusion: The results explain that the miRNA gene polymorphisms may have correlation with the susceptibility to myeloma disease.
- 1 January 2024
- Published by Medknow in Medical Journal of Babylon
- Vol. 21 (1) , 52-56
Open AccessDetection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical methods
Background: MicroRNA (miRNA) is a short, single-stranded, non-coding sequence of RNA that does not translate into proteins. Because of their ability to control gene expression, recent studies have shown that these short, non-coding sequences play an important role in cancer. So that, detection the polymorphisms or variants in miRNA genes may help to identify their correlation to cancer susceptibility. Objectives: Study the polymorphisms in miRNA genes or variants miRNA genes and their correlation with myeloma disease. Materials and Methods: Twenty samples were collected from people who visited Marjan Hospital in Province of Babylon, Iraq, from February to July 2022. In addition, 20 samples from healthy people were collected as control. Genotyping of miRNA was accomplished using the polymorphism techniques of polymerase chain reaction and single strand conformation polymorphism (SSCP). DNA sequencing was also applied to categorize all the ranges of SSCP models detected using only gel imaging. Results: The genotypes obtained in this experiment verified that several single nucleotide polymorphisms were obtained between 5-band and 6-band miRNA National center for biotechnology information Primer3 plus reference. Conclusion: The results explain that the miRNA gene polymorphisms may have correlation with the susceptibility to myeloma disease.
- Open Access
- 6 June 2023
- Published by University of Alkafeel in Maaen Journal for Medical Sciences
- Vol. 2 (1) , 7
Lipid nanoparticles as theranostic vesicle
Lipid nanoparticles (LNP) are the most well-studied first approved nanomedicine for drug delivery of therapeutic and vaccine formulation products. However, their nature is under constant investigation especially their liquid crystal state which leads to their complex biological behavior. LNPs are generally regarded as safe (GRAS) and suitable for ameliorating the toxicity and/or improving the pharmacokinetics of newly approved biomaterials with promising functionality and effects. During the past decade, many promising theranostic applications for LNPs have emerged resulting in huge potential for them in this field. Although there is progress in theranostic application, the gap between the bench and clinical application is undeniable, and that must be addressed to exploit the benefits of these nanomedicines for society.
- 6 June 2023
- Published by University of Alkafeel in Maaen Journal for Medical Sciences
- Vol. 2 (1) , 7
Open AccessLipid nanoparticles as theranostic vesicle
Lipid nanoparticles (LNP) are the most well-studied first approved nanomedicine for drug delivery of therapeutic and vaccine formulation products. However, their nature is under constant investigation especially their liquid crystal state which leads to their complex biological behavior. LNPs are generally regarded as safe (GRAS) and suitable for ameliorating the toxicity and/or improving the pharmacokinetics of newly approved biomaterials with promising functionality and effects. During the past decade, many promising theranostic applications for LNPs have emerged resulting in huge potential for them in this field. Although there is progress in theranostic application, the gap between the bench and clinical application is undeniable, and that must be addressed to exploit the benefits of these nanomedicines for society.